Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04535167 · ClinicalTrials.gov registry record · Phase 1
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT04535167 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 26 participants.
The verdict
NCT04535167, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2 virus infection.
Interventions
- DRUG Placebo
- DRUG PF-07304814
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2021-06-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04535167
The ClinicalTrials.gov registry entry for NCT04535167 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04535167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04535167 about?
NCT04535167 is a clinical study titled "First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.". It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2 virus infection.
What is the current status of trial NCT04535167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2020-09-09. Estimated completion is 2021-06-07.
What interventions are being tested in trial NCT04535167?
The interventions under investigation include: Placebo (DRUG), PF-07304814 (DRUG).
Who is sponsoring clinical trial NCT04535167?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.